期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

谷氨酸受体调节剂对N2a细胞中DISC1及Camk2γ的影响 被引量：1

Effects of Glutamate Receptors Agents on the Expression of DISC1 and Camk2γ in N2a Cells
下载PDF
导出
摘要 目的观察谷氨酸受体调节剂对小鼠神经瘤N2a细胞中精神分裂症断裂基因1(DISC1)及钙/钙调素依赖性蛋白激酶2γ(Camk2γ)的影响。方法将N2a细胞随机分为4组(n=6),分别加入DMSO(D组,对照组)、1μmol/L氯胺酮(K组)、2μmol/L MK-801(M组)及2μmol/L NBQX(N组)。采用Western blotting检测DISC1及Camk2γ表达。结果与D组相比,K组及M组DISC1表达下调,N组DISC1表达上调(P<0.05);K组及M组Camk2γ下调,N组Camk2γ下调(P<0.05)。结论谷氨酸受体调节剂影响小鼠神经瘤N2a细胞中DISC1及Camk2γ的表达,这可能与谷氨酸受体调节剂诱发精神分裂样不良反应有关。 Objective To observe the effects of glutamate receptors agents on the expression of disrupted in schizophrenia 1 （DISC1） and Ca^2＋/calmodulin -dependent protein kinase 2γ （Camk2γ） in mouse neuroblastoma N2a cells. Methods N2a cells were randomly divided into 4 groups （ n = 6） ： DMSO （ group D, control group） , 1μmol/L ketamine （ group K） , 2μmol/L MK - 801 （ group M） and 2μmol/L NBQX （group N）. DISC1 and Camk2γ expression was measured by Western blotting. Results Compared with group D, DISCI decreased in groups K and M while increased in group N （P 〈 0.05） and Camk2γ increased in groups K and M while de- creased in group N （P 〈 0.05）. Conclusion Glutamate receptors affect the expression of DISC1 and Camk2γ in mouse neuroblastoma N2a cells, which probably contributes to the glutamate receptor agents -induced schizophrenia -like adverse effects.
作者 王楠 李晓敏 杨春 杨建军 周志强
机构地区 南京大学医学院南京军区南京总医院麻醉科
出处 《医学研究杂志》 2012年第9期35-37,共3页 Journal of Medical Research
基金 国家自然科学基金资助项目(30872424) 全军"十二五"科研面上项目(CWS11J017) 江苏省科教兴卫工程(医学重点人才)(RC2011136)
关键词 谷氨酸受体 精神分裂症断裂基因1 钙/钙调素依赖性蛋白激酶2γ N2A细胞 Gutamate receptor Disrupted in schizophrenia 1 Ca^2＋/ealmodulin -dependent protein kinase 2γ N2a cells
分类号 R741 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献8

  • 1Francis PT. Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine[ J]. Curt Mol Pharmacol, 2009, 2(1) :77 -82.
  • 2Arai AC, Kessler M. Pharmacology of ampakine modulators: from AM-PA receptors to synapses and behavior[ J]. Curr Drug Targets, 2007, 8 (5) :583 -602.
  • 3Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment[ J ]. Psychopharmacology ( Bed), 2011, 213 (2 - 3 ) :289 - 305.
  • 4Hennah W, Thomson P, Pehonen L, et al. Genes and schizophrenia: beyond schizophrenia: the role of DISC1 in major mental illness[ J]. Schizophr Bull, 2006, 32(3) :409 -416.
  • 5Brandon NJ, Millar JK, Korth C, et al. Understanding the role of DISC1 in psychiatric disease and during normal development [ J]. J Neurosci, 2009, 29(41):12768- 12775.
  • 6Ramsey AJ, Milenkovic M, 01iveira AF, et al. Impaired NMDA recep- tor transmission alters striatal synapses and DISC1 protein in an age - dependent manner[ J]. Proc Natl Acad Sci U S A, 2011, 108 (14) : 5795 - 5800.
  • 7O'Neill MJ, Bleakman D, Zimmerman DM, et al. AMPA receptor po- tentiators for the treatment of CNS disorders [ J]. Curr Drug Targets CNS Neurol Disord, 2004, 3(3) :181 -194.
  • 8Tombes RM, Faison MO, Turbeville JM. Organization and evolution of multifunctional Ca2./CaM - dependent protein kinase genes [ J ]. Gene, 2003, 322(11) :17 -31.

同被引文献11

  • 1汪春运,余琳.氟伏沙明在精神科的应用[J].医学研究生学报,2006,19(1):89-91. 被引量：18
  • 2Niitsu T, Fujisaki M, Shiina A, et al. A randomized, double- blind,placebo-controlled trial of fluvoxamine in patients with schizophrenia:a preliminary study[J]. J Clin Psychophar- macol, 2012,32(5) : 593-601.
  • 3Sugimoto Y, Tagawa N, Kobayashi Y, et al. Involvement of the sigma-1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetine[J]. Eur J Pharmacol, 2012, 696 (1-3) : 96-100.
  • 4Gomes MP, Millen TA, Ferreira PS, et al. Prion protein com- plexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells [J]. J Biol Chem,2008,283(28) : 19616-19625,.
  • 5Niitsu T, lyo M, Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases[J]. Curr Pharm Des, 2012,18(7) : 875-883.
  • 6Hindmareh I, Hashimoto K. Cognition and depression:the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered[J]. Hum Psychopharmacol, 2010,25(3) : 193-200.
  • 7Hashimoto K. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia[J]? CNS Neurol Disord Drug Targets, 2009,8(6) : 470-474.
  • 8Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy[J]. J Neurosci, 2009,29(21) : 6964-6972.
  • 9Kitagishi Y, Kobayashi M, Kikuta K, et al. Roles of PI3K/ AKT/GSK3/mTOR pathway in cell signaling of mental illnesses[J]. Depress Res Treat, 2012,20 (12): 7525-7563.
  • 10Tombes RM, Faison MO, Turbeville JM. Organization and evolution of muhifunetional Ca^2+/CaM-dependent protein kinase genes[J]. Gene, 2003,322 (11) : 17-31.

引证文献1

医学研究杂志
2012年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部